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The human Polyomavirus JC virus (JCV) utilizes cellular proteins for viral replication and transcription in the host cell nucleus. These cellular
proteins represent potential targets for antiviral drugs against the JCV. In this study, we examined the antiviral effects of the pharmacological cyclin-
dependent kinase (cdk) inhibitor R-Roscovitine, which has been shown to have antiviral activity against other viruses. We found that Roscovitine
significantly inhibited the viral production and cytopathic effects of the JCV in a JCV-infected cell line. Roscovitine attenuated the transcriptional
activity of JCV late genes, but not early genes, and also prevented viral replication via inhibiting phosphorylation of the viral early protein, large T
antigen. These data suggest that the JCV requires cdks to transcribe late genes and to replicate its own DNA. That Roscovitine exhibited antiviral activity
in JCV-infected cells suggests that Roscovitine might have therapeutic utility in the treatment of progressive multifocal leukoencephalopathy (PML).
© 2007 Elsevier Inc. All rights reserved.Keywords: JC virus; Progressive multifocal leukoencephalopathy; Antiviral drug; Cyclin-dependent kinase; RoscovitineIntroduction
Progressive multifocal leukoencephalopathy (PML) is a fatal
demyelinating disease of the central nervous system (CNS) that
is caused by the human Polyomavirus JC virus (JCV). PML is
characterized by a selective destruction of oligodendrocytes that
leads to multiple areas of demyelination and the attendant loss of
motor and sensory function and cognitive impairment. PML is
often observed in individuals with compromised immune
systems, such as those with acquired immunodeficiency syn-
drome (AIDS), advanced stage malignant tumors, or recent
organ transplantation with immunosuppressive therapy. The
incidence of PML is increasing due to the AIDS pandemic. To⁎ Corresponding author. Department of Molecular Pathobiology, Hokkaido
University Research Center for Zoonosis Control, N18, W9, Kita-ku, 060-0818,
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doi:10.1016/j.virol.2007.08.034date, there is no effective and specific therapy for PML. The only
therapeutic option for patients with PML is highly active
antiretroviral therapy (HAART), which has been shown to
improve the prognosis for AIDS-related PML patients (Albrecht
et al., 1998). However, a substantial number of PML patients are
unresponsive to antiretrovirals and some patients develop an
immune reconstitution inflammatory syndrome as a result of
antiretroviral treatment (Collazos et al., 1999). In fact, a multi-
center study of HIV-positive patients with PML failed to show a
significant benefit of cytarabine or cidofovir in addition to
antiretroviral treatment (Hall et al., 1998; Marra et al., 2002).
Since the 5-hydroxytryptamine-2A serotonin receptor has been
recently identified as a cellular receptor for JCV (Elphick et al.,
2004), serotonin antagonists are under consideration as thera-
peutic drugs for preventing the spread of JCV in the CNS. In
addition, small interfering RNA-based therapeutics against JCV
may be useful if the siRNA delivery system into the CNS is
developed (Orba et al., 2004; Radhakrishnan et al., 2004).
174 Y. Orba et al. / Virology 370 (2008) 173–183The JCV is a small double-stranded DNA virus that encodes
early proteins (large T antigen, small t antigen, and T′ antigen)
and late proteins (VP1, VP2, VP3, and agnoprotein) but does
not encode its own kinases. Replication of the JCV needs the
cellular replication proteins of host cells, and specific cellular
factors in JCV-permissive cells are likely to play a role in the
replication of the JCV. The JCV shares 69% sequence homo-Fig. 1. Effects of Rosco on CPE of JCV-infected cells and JCV propagation. (A) Ce
(control) or Rosco (10 μM, dissolved in DMSO). Cells were treated every 3 days from
time points. (B) Induction of morphologic changes in JCV-inoculated IMR-32 cells tre
iodide (PI) staining (red color). JCV-infected cells were stained with anti-VP1 antibo
(C) Hemagglutination activity (HA) of the JCV in JCI cells treated with DMSO or Ro
indicated as the normalized value for the cells treated with DMSO. These data repr
⁎pb0.01 versus the value for the cells treated with DMSO.logy at the nucleotide level with simian virus 40 (SV40), and
JCVand SV40 belong to the Polyomavirus family. Both viruses
produce large T antigen (TAg), which is necessary for the
replication of viral DNA. It has been reported that phosphor-
ylation of a single residue at threonine 124 (T124) by a kinase
such as the cdc2 kinase (also known as cdk1) of SV40 TAg is
important for the viral DNA replication (McVey et al., 1989,ll growth of IMR-32 cells or JCV-inoculated IMR-32 cells treated with DMSO
8 days post infection (d.p.i.) and the number of cells was counted at the indicated
ated with DMSO or Rosco at 23 d.p.i. Dead cells were examined with propidium
dy and Alexa 488-labeled secondary antibody (green color). Scale bars, 50 μm.
sco (5 or 10 μM) for 12 days. The HA titers of cell extracts from 1×106 cells are
esent the mean±SD of the results from at least three independent experiments.
175Y. Orba et al. / Virology 370 (2008) 173–1831993). Mutational analysis of the T124 residue of SV40 TAg
has been shown to result in a replication defect in the initial
steps of the sequence-specific unwinding of the core origin
(Kim et al., 2002; McVey et al., 1996; Moarefi et al., 1993).
Likewise, the cdk recognition sequence is conserved in the JCV
TAg at threonine 125 (T125) (Swenson and Frisque, 1995).
Mutation of the T125 residue of JCV TAg abolishes replication
of JCV DNA (Swenson et al., 1996), suggesting that phos-
phorylation of the cdk recognition site of TAg is important for
proper TAg function in viral DNA replication.Fig. 2. Effects of Rosco on the expression of viral proteins. (A) Immunoblot analysis
and 12 days after DMSO or Rosco (5 or 10 μM) treatment were used for immuno
cytometry analysis of JCI cells treated with DMSO or Rosco (10 μM) for 10 days
secondary antibody (black line) or secondary antibody only (gray dotted line). The per
of viral proteins in JCV-inoculated IMR-32 cells. IMR-32 cells were inoculated
Immunoblotting was performed using the same antibodies as in panel A.Cyclin-dependent kinases (cdks) are a family of serine/threo-
nine kinases involved in the regulation of the cell cycle (cdk1, 2,
3, 4, 6, and 7), transcription (cdk7, 8, and 9), and neuronal
functions (cdk5). The cdks associate with cyclin subunits and
regulate the cell cycle by phosphorylating distinct cellular
proteins, including transcription factors, histones, cytoskeletal
proteins, and tumor suppressor proteins. The activity of cdks is
positively regulated by cdk binding to a cyclin subunit and by
phosphorylation on the kinase subunit in well-defined sites.
Conversely, cdks are negatively regulated by phosphorylation atof viral proteins in JCI cells. Lysates prepared from JCI cells collected at 3, 6, 9,
blotting with anti-TAg, -VP1, -Agno, and -alpha-tubulin antibodies. (B) Flow
. TAg expressing cells were stained with anti-TAg antibody and FITC-labeled
centage of TAg-positive cells is indicated on the panels. (C) Immunoblot analysis
with the JCV and treated with DMSO or Rosco (10 μM) for 4 or 6 days.
176 Y. Orba et al. / Virology 370 (2008) 173–183different sites or by binding a natural cdk inhibitor, such as a
member of the Cip/Kip or INK4 family.
Because cdks are required for the replication of many clin-
ically important viruses, pharmacological cdk inhibitors (PCIs)
have been proposed as potential antiviral drugs in recent years
(Schang, 2002, 2004). R-Roscovitine (Rosco) is one of the
purine-type PCIs that specifically inhibits cdk1, 2, 5, 7, and 9 by
competing with ATP binding in the ATP binding pocket of the
cdks (Canduri et al., 2004; De Azevedo et al., 1997; McClue
et al., 2002; Meijer et al., 1997). Rosco has been proven non-
toxic in animal models and is currently in phase II clinical trials
to treat cancer and glomerulonephritis (Benson et al., 2007;
McClue et al., 2002; Raynaud et al., 2005). Additionally, the
study for tissue distribution and pharmacokinetics of Rosco in
rat shows that brain exposure to Rosco is about 30% of that
found in plasma (Vita et al., 2005). These data indicate that
Rosco crosses the blood brain barrier probably because of the
lipophilic character and low molecular weight (molecular
weight=354) of the drug (Vita et al., 2005).
Since we hypothesize that Rosco inhibits viral replication
via decreased JCV TAg function, the aim of this study was to
examine the effects of Rosco on JCV proliferation. The results
of this study show that Rosco significantly inhibited viral
production and expression of viral proteins in JCV-infected cells
by preventing viral replication and transcriptional activity of
JCV late genes. We also confirmed that Rosco decreased phos-
phorylation of the cdk recognition motif on TAg. Thus, Rosco
exhibits antiviral activity against JCV infection in vitro.Fig. 3. Effects of Rosco on viral mRNA production in JCI cells. JCI cells were treated
the cells. Viral mRNAs were measured by quantitative RT-PCR using specific primer
actin mRNA and are expressed as the ratio of mRNA levels in Rosco-treated cells to D
three independent experiments. ⁎pb0.01 versus the value for the cells treated withResults
Rosco inhibits JCV-induced CPE and JCV production
To test whether Rosco affected JCV propagation in host cells,
we initially observed cell growth and the cytopathic effects
(CPE) of the JCV (Wroblewska et al., 1980) using the JCV-
permissive cell line, IMR-32. IMR-32 cells were inoculated with
the JCV and at 8 days post-infection (d.p.i.), either DMSO or
10 μMRosco (dissolved in DMSO)were added to the cells every
3 days for 30 days. At 23 d.p.i., CPE characterized by cell
shrinkage and aggregation was observed in the control cells that
were treated with DMSO alone (Figs. 1A and B). These aggre-
gated cells were stained with propidium iodide, and JCV late
protein, VP1 was also recognized in the cells (Fig. 1B). How-
ever, cells treated with Rosco did not show CPE and cell death
even after inoculation with the JCV (Figs. 1A and B). Further-
more, 1-month treatment with Rosco (10 μM) did not induce
apparent cell growth arrest of the IMR-32 cells (Fig. 1A).
We next investigated whether Rosco could affect JCV
production using JCI cells, which come from an IMR-32-
derived JCV-producing cell line in which approximately 10 to
20% of the cells are positive for JCV encoding protein
(Nukuzuma et al., 1995). To test the effect of Rosco on JCV
production in JCI cells, we measured viral HA titers of the cells
treated with DMSO or Rosco (5 or 10 μM) for 12 days. The HA
titer was significantly and dose-dependently decreased in cells
treated with Rosco compared to cells treated with DMSOwith DMSO or Rosco (10 μM) for 4 or 12 days and total RNAwas isolated from
sets for JCV TAg, VP1, and Agno. The data are normalized to the amount of beta
MSO-treated cells. These data represent the mean±SD of the results from at least
DMSO.
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production and cell death caused by JCV infection without
affecting host cell growth.
Rosco inhibits the expression of JCV proteins
Next we examined the expression of viral proteins when JCI
cells were treated with DMSO or Rosco (5 or 10 μM) every
3 days for 12 days. Rosco dose-dependently decreased
expression of TAg at 3 days and decreased expression of VP1
and agnoprotein (Agno) at 9 days (Fig. 2A). We also examined
the number of JCV-infected cells in JCI cells treated with Rosco.
Flow cytometry analysis indicated that TAg-expressing cells
were substantially decreased after treatment with 10 μM Rosco
for 10 days (Fig. 2B). We did not observe a decrease in early and
late protein expression until 3 and 9 days, respectively, because
the JCV genome had already proliferated in JCI cells and the
stage of JCV infection in each cell was diverse in JCI cells.
Therefore, we examined the effect of Rosco on the expression ofFig. 4. Effects of Rosco on JCVearly and late promoter activity. (A) Luciferase assay
IMR-32 cells were transfected with luciferase reporter plasmids containing the JCVe
Basic). Cells were cultured with DMSO or Rosco for 48 h and the luciferase activity o
from at least three independent experiments. ⁎pb0.01 versus the value for the cells trea
cells were transfected with an empty vector (pGL3), JCVearly genes (pJCE), or late ge
the total RNA extracted from the cells. To detect pJCE- or pJCL-specific transcripts,
VP1, respectively. GAPDH was used as an internal control. RNA from JCI cells werviral proteins in JCV-inoculated IMR-32 cells. IMR-32 cells
were inoculated with the JCV and simultaneously treated with
DMSO or Rosco (10 μM) for 4 or 6 days. As expected, Rosco
markedly suppressed the expression of both early and late
proteins, whereas viral proteins were detected at 4 days after
JCV inoculation in the cells treated with DMSO (Fig. 2C).
To confirm whether the reduction of viral protein expression
by Rosco was caused by the inhibition of viral protein produc-
tion, we measured the amount of viral mRNA in JCI cells
treated with Rosco (10 μM) for 4 or 12 days. Using quantitative
RT-PCR, we found that the amount of early and late mRNAwas
significantly decreased at 4 and 12 days after treatment with
Rosco (Fig. 3). Thus, Rosco potently decreased overall viral
burden in JCV-infected cells.
Rosco inhibits the transcriptional activity of JCV late genes
Although expressions of both early and late mRNAs were
decreased in JCI cells treated with Rosco (Fig. 3), these resultsfor the JCV promoter. After pretreatment with DMSO or Rosco (10 μM) for 48 h,
arly promoter (pGL3-early), late promoter (pGL3-Late), or empty vector (pGL3-
f the cell extracts was measured. These data represent the mean±SD of the results
tedwith DMSO. (B) Transcription assay for the JCVearly and late genes. IMR-32
nes (pJCL) and treated with DMSO or Rosco for 48 h. RT-PCRwas performed on
PCR analysis of the synthesized cDNAwas carried out using primers for TAg or
e used as positive control.
Fig. 5. Effects of Rosco on JCV replication activity. (A) Representative Southern
blot from the replication assay. IMR-32 cells were transfected with plasmids
containing the JCV replication origin (pBS-JCori) and either a TAg expression
vector or mock vector and were cultured with DMSO or Rosco (10 μM) for 48 h.
Low molecular weight DNAwas isolated from cells and digested with EcoRI or
EcoRI and DpnI. Southern blots were performed by hybridization of a
digoxigenin-labeled probe against an ampicillin-resistant gene fragment of pBS-
JCori. Immunoblot (IB) analysis of Flag-TAg expression in these cells is also
indicated. (B) The signals for replicated DNA were quantified with an image
analyzer and plotted as a value that is normalized to the cells treated with
DMSO. These data represent the mean±SD of the results from three
independent experiments. ⁎pb0.01 versus the value for the cells treated with
DMSO. (C) Cellular genomic replication was measured by BrdU incorporation.
BrdU was incorporated into IMR-32 cells for 1 h after treatment with DMSO or
Rosco (10 μM) for 48 h. The percentage of BrdU-positive cells was measured by
flow cytometry analysis. (D) Effects of Rosco on TAg phosphorylation by cdk.
Lysates prepared from JCI cells collected at 48 h after DMSO or Rosco (10 μM)
treatment were used for immunoprecipitation (IP) with an anti-TAg antibody or
normal mouse IgG. Immunoblotting (IB) was performed with an anti-TAg
antibody and anti-phospho-threonine proline (pTP) antibody that recognizes cdk
phosphorylation sites. Immunoblots were also performed on total lysates using
anti-TAg and actin antibodies.
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measured in the presence of early and late proteins and viral
DNA and not represent transcriptional activity of the JCV
promoter itself. Therefore, to investigate whether Rosco-
induced suppression of viral mRNA production is related to
the viral transcriptional activity, we examined activity of the
JCV promoter in IMR-32 cells in the presence or absence of
Rosco. Because the transcriptional control region (TCR) of the
JCV is comprised of the bidirectional promoter that drives
viral early and late transcripts in opposite directions, we
performed a luciferase assay using luciferase reporter plasmids
containing the JCV early or late promoter in IMR-32 cells.
When cells were treated with Rosco (10 μM) for 48 h after
transfection with reporter plasmids, the transcriptional activity
of the JCV late promoter was significantly decreased
compared to that of control cells, whereas the activity of the
early promoter was unchanged by Rosco (Fig. 4A). Further-
more, these results were confirmed using plasmids designated
pJCE or pJCL that contained the JCV TCR and the
downstream early or late JCV genome, respectively. Consis-
tent with the results of the luciferase assay, expression of the
VP1 transcript was inhibited by Rosco treatment (Fig. 4B).
Thus, Rosco inhibited transcriptional activity of the JCV late
genes, but not early genes.
Rosco inhibits JCV replication
JCV TAg has the cdk recognition motif at threonine 125
(T125), and it has been suggested that phosphorylation of this
site by cdk plays a key role in the replication activity of TAg.
Therefore, we examined the effects of Rosco on JCV
replication using a DpnI replication assay in IMR-32 cells.
Because JCV replication is dependent on TAg, IMR-32 cells
were co-transfected with a TAg expression vector and pBS-
JCori, which contains the JCV TCR including the replication
origin. After treatment with DMSO or Rosco (10 μM) for
48 h, viral DNA replication was assessed by Southern blot
analysis of EcoRI and DpnI-digested low molecular weight
DNA extracted from the cells. We detected DpnI-resistant
replication products in the presence of TAg, whereas
replication was significantly decreased after treatment with
Rosco (Figs. 5A and B). We also used a BrdU incorporation
assay to show that Rosco did not affect the replication of
cellular DNA (Fig. 5C). In this experiment, the amounts of
exogenously expressed TAg were not different between
DMSO and Rosco-treated cells (Fig. 5A); therefore, the
inhibition of viral DNA replication by Rosco is not likely to
result from TAg depletion, but rather a result of post-
translational modification of TAg, for example, by phosphor-
ylation. Thus, TAg that was immunoprecipitated from JCI cells
was probed with an antibody that recognizes cdk threonine
phosphorylation sites to examine if Rosco affected the phos-
phorylation of the cdk recognition motif on TAg. As we
expected, phosphorylation of the cdk recognition motif on
TAg was markedly decreased in the cells treated with Rosco
(Fig. 5D). These data indicate that Rosco inhibited JCV rep-
lication by preventing the phosphorylation of TAg.
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Several recent studies have suggested that the effects of
Rosco in vitro might have antiviral therapeutic utility against
human cytomegalovirus (HCMV), herpes simplex virus (HSV)
type 1 and 2, human immunodeficiency virus type-1 (HIV-1),
Epstein-Barr virus (EBV), varicella-zoster virus (VZV), and
some other viruses (Bresnahan et al., 1997; Kudoh et al., 2004;
Schang et al., 1998; Taylor et al., 2004; Wang et al., 2001).
Rosco has been shown to inhibit not only viral DNA
replication, but also transcription, post-translational modifica-
tion, and subcellular localization of viral proteins (Davido et
al., 2002; Habran et al., 2005; Sanchez et al., 2004; Sanchez
and Spector, 2006). Moreover, Rosco exerts these effects
against mutant strains of these viruses that are resistant to
conventional antiviral drugs because it targets cellular cdks
instead of viral proteins (Agbottah et al., 2005; Schang et al.,
2002).
In this study, we demonstrated that Rosco exhibits antiviral
effects against the JCV. Rosco effectively suppressed viral
propagation and the expression of viral proteins in JCI cells
and JCV-inoculated IMR-32 cells at 10 μM. Transcription and
replication assays for the JCV indicated that the antiviral
effects of Rosco on the JCV were responsible for the
suppression of both the transcriptional activity of the JCV
late promoter and the replication of viral DNA. In addition to
TAg, many cellular transcription factors such as NF1, NF-κB,
Tst-1, YB-1, and AP1 are known to be involved in controlling
JCV late transcription (Amemiya et al., 1989; Kerr et al., 1994;
Ranganathan and Khalili, 1993; Sadowska et al., 2003; Wegner
et al., 1993). Since Rosco inhibited the transcription of late
proteins in the absence of TAg, it seems likely that some
cellular protein(s), including unknown molecule(s) which
transactivate the JCV late promoter, are regulated by cdk. As
for the effect of Rosco on viral replication, the inhibition of
TAg phosphorylation at the cdk recognition motif by Rosco
results in defective viral replication because functional
phosphorylated TAg is essential for JCV replication. These
data suggest that the JCV requires cdk for the transcription of
late genes, as well as for replication of its own DNA. It is
known that JCV-infected oligodendrocytes in the brains of
individuals with PML overexpress Ki-67, cyclin A, and cyclin
B1, which are normally regulated in a cell-cycle-specific
manner (Ariza et al., 1998). The JCV is more likely to induce
cellular cdk/cyclin activity for self-replication of its genome in
mature oligodendrocytes, which are thought to exist in a non-
proliferating state (Ruffini et al., 2004).
Many antiviral drugs have been designed to target viral
proteins to avoid cytotoxicity. However, this approach seems to
be difficult with small viruses like the JCV that encode a limited
number of proteins. Alternatively, antiviral drugs that target
cellular proteins might exhibit activity against many viruses,
including small viruses, because the replication of many viruses
requires cellular proteins. Antiviral drugs that target cellular
proteins seem to be active even against mutated viruses that are
resistant to conventional antiviral drugs. Furthermore, antiviral
reagents that target common cellular proteins that are requiredby different viruses might be particularly effective treatments
for infections of multiple viruses, for example, JCV and HIV in
the case of AIDS-related PML. A potential drawback of
targeting cellular proteins is the presumably greater risk of
cytotoxicity or side-effects; therefore, the potential cytotoxic
effects of antiviral drugs that target cellular proteins should be
carefully examined in vivo. Thus far, no major toxic effects of
Rosco have been reported in pre-clinical and clinical trials, even
though PCIs target cellular cdks (Benson et al., 2007; McClue et
al., 2002; Raynaud et al., 2005). Furthermore, pharmacokinetic
data for Rosco indicates that it crosses the blood brain barrier in
rat (Vita et al., 2005), which is important for the treatment of
CNS diseases such as PML. Thus, Rosco shows substantial
promise as a clinical antiviral drug that might be effective
against PML.
Materials and methods
Cells and virus infection
Cells from the human neuroblastoma cell line IMR-32
(HSRRB, Osaka, Japan) and JCV-producing JCI cells that were
derived from the IMR-32 cell line (Nukuzuma et al., 1995) were
maintained at 37 °C and 5% CO2 in Dulbecco's minimal
essential medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), antibiotics, 2 mM L-glutamine, and 0.1 mM non-
essential amino acids.
For virus preparation, JCI cells were harvested and sus-
pended in Tris-HCl (pH 7.5) containing 0.2% bovine serum
albumin (BSA), frozen and thawed three times, and then treated
with 0.05 U/ml of neuraminidase type V (Sigma, St. Louis,
MO) at 37 °C for 16 h. After incubation at 56 °C for 30 min, cell
lysates were centrifuged at 1,000×g for 10 min. The super-
natant was quantified by hemagglutination (HA) assays and
stored at −80 °C until use. For virus infection, IMR-32 cells
were inoculated with 200 HA/ml of the JCV in growth media for
24 h. Following inoculation, the cells were cultured in fresh
media until assay.
Chemicals and antibodies
A 50 mM stock solution of Roscovitine (Calbiochem,
Darmstadt, Germany) was prepared in dimethylsulfoxide
(DMSO, Sigma).
The anti-VP1 antibody was generated by immunizing rabbits
with virus-like particles prepared from recombinant VP1
expressed in Escherichia coli (Komagome et al., 2002). The
anti-agnoprotein antibody was generated by immunizing rabbits
with a synthetic peptide from the agnogene of the Mad1 strain of
the JCV (Endo et al., 2003). The monoclonal anti-SV40 TAg
(Ab-2) antibody, which has been previously shown to cross-
react with the JCV large T (Okada et al., 2002), was obtained
fromCalbiochem. Themonoclonal anti-actin (Chemicon, Teme-
cula, CA), monoclonal anti-α-tubulin (Sigma), monoclonal anti-
phospho-Threonine cdk substrate (Cell Signaling Technology,
Beverly, MA), and Rat monoclonal anti-BrdU (Abcam, Cam-
bridge, UK) antibodies were commercially obtained.
180 Y. Orba et al. / Virology 370 (2008) 173–183Drug treatment and viable cell count
Either DMSO or 10 μM Rosco was diluted in media and
added to cells every 3 days for 30 days when the cells were
passaged. At the same time, the number of cells was determined
by counting the viable cells with a hemocytometer using the
Trypan blue dye exclusion assay. For each period, three dishes of
each group were counted. At 23 d.p.i., cells were stained with
2 μg/ml of propidium iodide (PI) in growth media, then CPE-
and PI-positive cells were evaluated under an inverted fluores-
cence/phase-contrast microscopy (Olympus, Tokyo, Japan).
Hemagglutination (HA) assay
JCV titers were assayed by hemagglutination of human type
O erythrocytes as described previously (Suzuki et al., 2001). JCI
cells were collected after treatment with 0 μM (DMSO only),
5 μM, or 10 μM of Roscovitine for 12 days. The media, with or
without Roscovitine, were changed every 3 days. The cells
(1×106) were washed in phosphate-buffered saline (PBS), re-
suspended with 50 μl of Tris-HCl (pH 7.5) containing 0.2%
BSA, and treated with 0.05 U/ml of neuraminidase as described
above. For the hemagglutination assay, two-fold serial dilutions
of the cell extract (25 μl) with PBS (pH 7.15) containing 0.2%
BSAwere made in 96-well, V-bottomed microplates. An equal
volume of 0.5% red blood cells in PBS (pH 7.15) was added to
each well. Cells were incubated at 4 °C for 3 h, at which point
the HA titer of virus was expressed as the highest dilution
resulting in hemagglutination.
Immunocytochemistry
JCV-infected IMR-32 cells were fixed for 3 min in 100%
methanol at −20 °C. After blocking with 1% BSA, cells were
incubated with anti-VP1 antibody (1:5,000) overnight at 4 °C,
and stained with Alexa Fluor 488-conjugated anti-rabbit immu-
noglobulin antibody (1:500; Invitrogen, Carlsbad, CA) for 1 h
at room temperature. Cells positive for VP1 were observed
under an inverted fluorescence/phase-contrast microscopy
(Olympus).
Immunoblotting and immunoprecipitation
Either IMR-32 cells inoculated with 800 HA units of the JCV
in 4 ml of growth media or JCI cells were collected at various
days in the presence or absence of Rosco and lysed in lysis buffer
[1% Triton X-100, 150 mM NaCl, 0.1% sodium dodecyl sulfate
(SDS), 1% deoxycholic acid, 10 mM Tris-HCl (pH 7.5), 5 mM
EDTA, 10% glycerol, 50 mM sodium fluoride, and 1 mM phe-
nylmethylsulfonyl fluoride]. After sonication and centrifu-
gation, 10 μg of protein was separated by SDS–PAGE and
examined by immunoblotting using anti-VP1 (1:5,000), anti-
agnoprotein (1:3,000), anti-SV40 large T (1:500), and anti-α-
tubulin (1:5,000) antibodies. After incubation with horseradish
peroxidase-conjugated secondary antibody (1:3,000; Biosource
International, Camarillo, CA), the signal was detected with an
ECL detection kit (GE Healthcare Bio-Sciences, Piscataway,NJ) and visualized with a LAS-1000 plus system (Fujifilm,
Tokyo, Japan).
For immunoprecipitation, cells were lysed in IP lysis buffer
[1% NP40, 150 mM NaCl, 10 mM Tris-HCl (pH 7.5), 1 mM
EDTA, 50 mM sodium fluoride, 1 mM phenylmethylsulfonyl
fluoride, 1 mM sodium orthovanadate, complete protease inhi-
bitor cocktail (Roche, Basel, Switzerland), and phosphatase in-
hibitor cocktail 1 (Sigma)]. Lysed protein was pre-incubated
with 20 μl of protein G Sepharose (GE Healthcare Bio-
Sciences) at 4 °C for 1 h. The supernatant was incubated with
anti-large T antibody or normal mouse IgG at 4 °C for 3 h.
Protein complexes were pulled down by incubation with protein
G Sepharose at 4 °C for 2 h and elution with SDS sample buffer
[125 mM Tris-HCl (pH 6.8), 10% 2-mercaptoethanol, 4% SDS,
10% sucrose, and 0.04% bromophenol blue] after washing with
IP lysis buffer. Immunoblotting was carried out with the anti-
phospho-Thr-Pro antibody (1:5,000) and horseradish peroxi-
dase-conjugated anti-mouse IgM (1:3,000; Zymed, South San
Francisco, CA) secondary antibody. Signals were analyzed as
described above.
Flow cytometry
For flow cytometry analysis of TAg expression, JCI cells
were collected, washed twice with PBS, suspended, and fixed
with 70% ice-cold ethanol overnight at 4 °C. Cells were washed
with PBS containing 0.5% fetal bovine albumin, incubated with
anti-SV40 TAg (Ab-2) antibody at room temperature for 2 h and
stained with fluorescein isothiocyanate (FITC)-conjugated anti-
mouse IgG (Beckman Coulter, Fullerton, CA) at room tem-
perature for 1 h. Flow cytometry experiments were carried out
using a FACSCalibur system (BD Biosciences, Sun Jose, CA)
and data were analyzed using Flowjo software (Tree Star,
Ashland, OR).
Reverse transcription (RT) and real-time PCR
For RNA extraction, JCI cells were collected after varying
durations of treatment with DMSO or 10 μMRoscovitine. Total
RNAwas isolated using an RNeasy Mini Kit (Qiagen, Valencia,
CA) according to the manufacturer's protocol. Total RNA (1 μg)
was treated with DNase I (Invitrogen) at 37 °C for 1 h in 10 μl of
reaction mixture. After inactivation of DNase I with 2.5 mM
EDTA at 65 °C for 15 min, 4 μl of reaction mixture was used for
RT using a Superscript first-strand synthesis system (Invitro-
gen). To confirm that the samples were not contaminated with
genomic DNA, RNase-free water was added instead of
Superscript II reverse transcriptase to at least one negative
control sample that was run in parallel. After confirmation of
cDNA amplification by conventional PCR for β-actin and VP1,
real-time PCR was performed using 0.5 μl of reaction mixture
containing cDNA, SYBR green PCR Master Mix (Applied
Biosystems, Foster City, CA), and gene-specific primer sets:
JCV large T, 5′-AAA GTT GCT CAT CAG CCT GAT TTT-3′
and 5′-CAT CCC ACT TCT CAT TAA ATG TAT TCC-3′; JCV
agnoprotein, 5′-CCA GCT GTC ACG TAA GGC TTC T-3′ and
5′-GTG CAAAAG TCC AGCAAAAAT TC-3′; JCV VP1, 5′-
181Y. Orba et al. / Virology 370 (2008) 173–183TCT AAA TGA GGA TCT AAC CTG TGG AAA-3′ and 5′-
GCC CAT TAG AGT GCA CAT TCATC-3′; β-actin, 5′-TTG
CCG ACA GGATGC AGA A-3′ and 5′-GCC GAT CCA CAC
GGA GTA CT-3′. After incubation of mixtures at 50 °C for
2 min and 95 °C for 10 min, the reaction was performed at 95 °C
for 15 s and 60 °C for 1min for 40 cycles using a GeneAmp 5700
Sequence Detection System (Applied Biosystems). The levels of
PCR products were analyzed with GeneAmp 5700 SDS
software (Applied Biosystems) and cycle times were normalized
to the cycle time ofβ-actin (Orba et al., 2004). All reactions were
confirmed by at least three independent experiments.
Luciferase assay and JCV transcription assay
Firefly luciferase reporter vectors pGL3-Basic and the
internal Renilla luciferase control vector phRL-TK were pur-
chased from Promega (Madison, WI). JCV early and late
reporter vectors (pGL3-Early or pGL3-Late) were constructed
from the regulatory regions of JCV Mad1 that has been
previously described (Okada et al., 2000). For the luciferase
assay, IMR-32 cells were seeded onto 24-well plates and the
cells were treated with DMSO or 10 μM Roscovitine for 48 h.
Each pGL3 reporter vector and phRL-TK control vector were
co-transfected into the cells using Lipofectamine 2000
(Invitrogen) according to the manufacturer's instructions. Six
hours after transfection, the media on each plate of cells were
replaced with fresh media containing DMSO or Roscovitine
and the cells were cultured for another 48 h. Luciferase activity
of the cells was measured using a dual-luciferase reporter assay
system (Promega) according to the manufacturer's instructions.
Luminescence intensity was measured with a Luminometer
(Turner Designs, Sunnyvale, CA). The firefly luciferase
activity data are presented as mean values±SD. The results
of each experiment were confirmed by three independent
transfections. We could not use Renilla luciferase activity for
normalization of the firefly luciferase activity because
Roscovitine seems to affect Renilla luciferase activity derived
from phRL-TK with the HSV-TK promoter (Schang et al.,
1999). The pJCE and pJCL reporter plasmids for the analysis
of JCV transcriptional activity were constructed as follows: the
early (E) and late (L) genes of the JCV Mad1 strain containing
the TCR and poly-adenylation signal were amplified by PCR
and subcloned into pGL3-basic that had been digested with
NheI and SalI. IMR-32 cells were seeded onto 6-well plates
and transfected with pGL3 basic, pJCE, or pJCL. Six hours
after transfection, the media on each plate of cells were
replaced with fresh media containing DMSO or Roscovitine
and the cells were cultured for 48 h. RNA extraction and
reverse transcription were performed as described above. To
detect pJCE- or pJCL-specific transcripts, PCR analyses of the
synthesized cDNA were carried out using Taq DNA polymer-
ase (Sigma). For detection of early transcripts, the primer pairs
of JCV large T: 5′-AAA GTT GCT CAT CAG CCT GAT TTT-
3′ and 5′-CAT CCC ACT TCT CAT TAA ATG TAT TCC-3′,
and for late transcripts, the primer pairs of JCV VP1: 5′-AAT
GTG CAC TCT AAT GGG CAA GC-3′ and 5′-CTA GGT
ACG CCT TGT GCT CTG-3′ were used. As a control, theprimer pairs of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH): 5′-TTC GTC ATG GGT GTG AAC CA-3′ and
5′-GGT CAT GAG TCC TTC CAC GAT AC-3′ were used.
DpnI replication assay
The full-length of the JCV Mad1 transcriptional control
region (TCR) was subcloned into a pBluescript II SK (+) vector,
which was designated pBS-JCori. The JCV TAg expression
vector pCXN2-JCTAg was constructed from pBR-Mad1. IMR-
32 cells were seeded onto 6 cm dishes and co-transfected with
pBS-JCori and pCXN2-JCTAg or a pCXN2 empty vector using
Lipofectamine 2000 according to the manufacturer's instruc-
tions. Six hours after transfection, the media on each plate of
cells were replaced with fresh media containing DMSO or
10 μM Roscovitine and cells were cultured for 48 h. Low-
molecular weight DNAwas isolated from the cells according to
the method of Hirt (1967). Extracts were treated with 0.5 mg/ml
Proteinase K at 56 °C for 1 h prior to phenol/chloroform/
isoamyl alcohol and ethanol precipitation. DNAwas suspended
in TE [10 mM Tris-HCl (pH 7.5), 1 mM EDTA (pH 8.0)]
containing 75 μg/ml RNase A. Sample DNA (5 μg) was
digested with EcoRI and DpnI, which selectively digest
transfected DNA that has been methylated during prokaryotic
replication, and digested products were separated by electro-
phoresis on a 1% agarose gel. DNA fragments were transferred
to a Hybond N+ membrane (GE Healthcare Bio-Sciences) by
capillary transfer using 20× SSC transfer buffer. The immobi-
lized DNA was detected using a digoxigenin-labeled DNA
probe that encoded a vector-derived ampicillin-resistant DNA
sequence (DIG high prime DNA labeling and detection starter
kit II, Roche). Signals were visualized with the LAS-1000 plus
system and replication activities were determined by quantify-
ing the intensity of the bands using Multi Gauge software
(Fujifilm). These results were confirmed by three independent
experiments.
BrdU incorporation
For detection of BrdU incorporation by flow cytometry,
10 μM of BrdU (Sigma) was incorporated into the cells for 1 h
after treatment with DMSO or 10 μM Roscovitine for 2 days.
Cells were washed twice with PBS and suspended and fixed
with 70% ice-cold ethanol overnight. DNAwas denatured with
2 N HCl in PBS containing 0.1% Triton-X at room temperature
for 20 min and neutralized with 0.1 M Sodium tetraborate (pH
9.0) for 5 min. Treated cells were washed in PBS containing
0.5% BSA, stained with Rat anti-BrdU antibody (1:50), and
stained with FITC-conjugated anti-Rat IgG antibody. BrdU-
positive cells were analyzed by flow cytometry as described
above.
Statistics
Statistical comparisons between experimental groups were
analyzed using the Student's t-test, and for all comparisons
pb0.05 was considered significant.
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